a Purpose PET/computed tomography (CT) has been shown to detect lesions in patients with pulmonary tuberculosis (PTB) and may be useful for assessing PTB disease in clinical research studies. However, radiation dose is of concern for clinical research in individuals with an underlying curable disease. This study aimed to determine whether PET/MR is equivalent to PET/CT in PTB.
Introduction
Several recent studies have indicated that PET/computed tomography (CT) has an important role to play in tuberculosis (TB) research, in particular, for the detection of subclinical TB [1] [2] [3] [4] [5] [6] . Soussan et al. [7] identified two distinct patterns when imaging pulmonary tuberculosis (PTB) using PET/CT: the lung pattern and the lymphatic pattern. The former describes a pattern of restricted and mildly hypermetabolic infection, whereas the latter is observed as an intense and systemic infection. However, in patients with a curable disease, such as TB, the radiation dose associated with PET/CT is a significant limitation for research studies that require a longitudinal assessment of outcomes with serial scans. In this respect, the newer technology of PET/MRI may have a distinct advantage.
Although many studies have compared PET/MR and PET/CT in the lung for oncological applications, to date, despite the increasing research interest for applying PETbased imaging in TB, there have been no studies comparing the two technologies for use in this disease. In general, fluorine-18-fluorodeoxyglucose ( 18 F-FDG) PET/ MR has been found to perform equally well as PET/CT in cancer imaging throughout the body [8] , but for imaging lung nodules that are small or of low 18 F-FDG avidity, PET/MR has been shown to be less optimal than PET/ CT [9] [10] [11] .
The aim of this study was to assess whether PET/MR is as effective as PET/CT in measuring the extent and activity of PTB lung lesions such that it may be used as an alternative to PET/CT in the burgeoning field of TB functional imaging to monitor the response to therapy in clinical trials.
Materials and methods

Patient cohort
Patients with a clinical diagnosis of PTB were recruited who showed characteristic symptoms and compatible radiographic findings plus microbiological confirmation with one or more of (i) sputum AFB smear positivity, (ii) GeneXpert (Cepheid Inc., Sunnyvale, California, USA) positivity or (iii) TB culture positivity. Exclusion criteria were having received TB treatment for more than 8 weeks, the presence of metallic implants that would render MRI unsafe and the presence of poorly controlled diabetes mellitus. Ten patients were prospectively recruited. This study was approved by the National Health Group Domain Specific Review Board, Singapore and informed, written consent was obtained from all participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
All procedures were performed during a single study visit. Patients received an intravenous injection of 18 F-FDG, with a mean injected activity of 129.0 4.1 MBq (mean SD). Five of the 10 patients underwent a PET/ MR scan (Siemens Biograph mMR; Siemens Healthineers, Erlangen, Germany), followed by PET/CT (Siemens mCT; Siemens Healthineers), whereas the remaining five were imaged first on PET/CT, followed by the PET/MRI.
PET/MR acquisition
The PET/MR studies were carried out using two 12-channel surface coils. PET data were acquired over the lungs for 15 min at 66.7 14.4 min (mean SD) postinjection when performing PET/MR first and 92.4 7.6 min when PET/MR data were acquired second. The PET acquisition was longer than what would typically be acquired clinically (when performing a PET/CT study) as the additional time on the bed is necessary for MRI acquisition. The PET data were reconstructed using Ordinary-Poisson Ordered-Subset Expectation-Maximization with three iterations and 21 subsets. A Gaussian postsmoothing filter of 6 mm fullwidth at half-maximum was applied. The matrix size was 172 × 172, with a voxel size of 4.17 × 4.17 mm and a slice thickness of 2.03 mm.
The MR protocol included Dixon imaging for MR-based Attenuation Correction (MRAC), precontrast and postcontrast T1-weighted Volumetric Interpolated Breathhold Examination (T1w-VIBE). T2-weighted Half Fourier Acquisition Single Shot Turbo Spin Echo (HASTE) and a navigated three-dimensional sampling perfection with application optimized contrasts using different flip-angle evolutions (3D-SPACE) sequences were also acquired. MR contrast agent (Magnevist; Bayer HealthCare, Berlin, Germany) was administered during the scan at a dose of 0.1 mmol/kg. Contrast was not administered to one patient because of a glomerular filtration rate of less than 60 ml/min/1.73 m 2 . Details of the MR acquisition parameters are shown in Table 1 .
PET/CT acquisition
Patients underwent a thoracic CT (120 kVp; quality reference mAs = 120; pitch = 1.5; 0.59 × 0.59 × 1.5 mm 3 voxel size) covering the whole lung in either one or two bed positions. With only two bed positions, PET data were acquired for 10 min/bed. This was to produce data with a noise level comparable to the PET/MR. The PET/CT study was carried out at 61.1 3.9 min after injection when performed first and 117.2 5.6 min as the second acquisition. Images were reconstructed with Ordinary-Poisson Ordered-Subset Expectation-Maximization (three iterations and 24 subsets) and a 6 mm postsmooth filter. The reconstructed PET image matrix was 200 × 200 with a voxel size of 4.07 × 4.07 mm and a slice thickness of 2.03 mm. Time-of-flight and point-spread function modelling capabilities of the PET/CT were not applied to produce images that were comparable with those of the PET/MR.
Image analysis Visual assessment
Images were analysed by two experienced medical image analysts (8 and 6 years' experience) using a methodology similar to that of Drzezga et al. [12] The scans were distributed between the two readers such that each assessed five PET/CT and five PET/MR studies, while not having to rate both scans for an individual patient. The aim was to reduce the possibility of introducing a bias in the detection of a lesion because of previous knowledge acquired from observing the other imaging modality.
For the assessment of the PET/MR studies, the PET data were used to locate regions in the lung parenchyma showing increased uptake. The T2-weighted HASTE and postcontrast T1w-VIBE were evaluated for the purposes of anatomical correlation with PET uptake. The PET/CT studies were assessed on the basis of increased PET uptake and the CT image was used to correlate structure with PET uptake. The correlation of structural imaging and PET uptake was rated on a lesionby-lesion basis using a scale of 0-3 (0, no anatomical correlation detectable; 1, uncertain anatomical correlation; 2, good anatomical correlation; and 3, excellent anatomical correlation). The readers were requested to identify all pulmonary lesions in each study. Observations of lymphadenopathy or extra-PTB were not included in the analysis. Given these lesions, a subset of five lesions per patient was selected on the basis of the order of appearance when viewing axial images from the apex of the lung to the diaphragm. A maximum of five lesions per patient were included to avoid an individual patient being over-represented. These subsets were then used for the subsequent quantitative analysis. To ensure that the same lesions were evaluated in both PET images, the readers were required to agree on the subset used for each patient, where all five lesions could be identified in both modalities. To compare the background activity in a healthy lung between the two scanners, a spherical (diameter: 3.0 cm) volume of interest (VOI) containing normal lung tissue was also determined for each patient.
In addition to the assessment of pulmonary lesions, all studies were graded in terms of (a) lesion detectability, (b) image quality and (c) global alignment of the PET and structural data. These were scored on a scale of 0-3, with 0 representing poor and 3 equating to excellent [12, 13] .
Quantitative comparison
Quantitative assessment of the PET/MR and PET/CT images was performed by standardized uptake value (SUV) analysis. PET uptake was evaluated by defining a 3D isocontour on the PET data, containing voxels that were of at least 50% of the maximum standardized uptake value (SUV max ) found from a spherical VOI placed over the lesion. mean standardized uptake value (SUV mean ) and SUV max were measured for the lesion isocontours and background VOIs. The volumes of the lesion isocontours were also measured.
A further analysis of the MR mu-maps was carried out. Each lesion was classified into one of four categories on the basis of the linear attenuation coefficient (LAC) assigned in the MRAC-based mu-map. Lesions were categorized as either soft tissue where the voxels of the segmented lesion were predominantly µ = 0.1 cm − 1 , fat, when µ = 0.0854 cm , or mixed, where at least 20% of voxels belonged to one tissue class, whereas the remaining voxels belonged to another. For each lesion VOI (five per patient) defined on the PET of the PET/CT study, the mean Hounsfield unit (HU) was calculated using the CT data. The HU values for the groups were compared.
Statistical analysis
All statistical analyses were carried out in R (v. 3.2.2) [14] . The visual ratings between PET/CT and PET/MR were assessed using Wilcoxon signed-rank tests for paired samples. For the SUV analysis, an analysis of variance of mixed factorial design with repeated measures was carried out to determine the effects of scanner and the time from injection to imaging. Bland-Altman analysis was carried out to compare PET/CT and PET/MR for the SUV mean and SUV max lesions. A P-value of less than 0.05 was considered significant.
Results
Ten participants with confirmed TB [age: 54.9 9.7 years (mean SD); range: 42.1-74.6 years; seven men] were recruited. Example PET/CT and PET/MRI of a TB patient are shown in Fig. 1 . Cavitary, 18 F-FDG-avid lesions can be observed in the apex of the left lung on both modalities. Figure 2 shows that structural abnormalities, as observed on CT (Fig. 2a) , can be identified using the postcontrast T1w-VIBE (Fig. 2c) . The T2w-HASTE shows increased signal intensity when fluid is present. A large pleural effusion can be observed with both MR (Fig. 2g) and CT (Fig. 2e) .
A total of 108 PTB lesions were detected on PET/MR and 112 on PET/CT. The four lesions that were not observed on PET/MR all had low mean SUVs (≤ 1.3). Two missed lesions were in the middle lobe and two in the lower lobe, where the effects of respiratory motion are greater. The visual ratings of overall lesion detectability, image quality and alignment are shown in Table 2 . There was no significant difference between PET/CT and PET/MR on the three measures. The rating of anatomical correlation between PET lesions and the associated structural imaging is shown in Table 3 . The highest agreement was found between PET and CT (2.8 0.7), with similar agreement for the T1w-VIBE (2.5 0.7) and T2w-HASTE (2.4 0.6).
The measured SUV mean and SUV max lesions were significantly lower on PET/MR compared with PET/CT. The mean SD SUV mean was 2.6 1.4 on PET/MR and 3.5 1.5 on PET/CT (P = 0.0005). The mean SUV max was 4.3 2.5 on PET/MR and 5.3 2.4 on PET/CT (P = 0.02). Bland-Altman analysis (Fig. 3) confirmed the lower SUV mean and SUV max values with PET/MR, but showed considerable variability. A significant effect of the time between injection and the commencement of imaging was found for SUV mean (P = 0.039) and SUV max It should also be noted that differences were observed in SUV mean and SUV max when calculated according to the scan order. When performing PET/CT first, the mean SUV mean was 3.9 1.3 for PET/CT and 3. No calcified lesions or miliary PTB were observed. Increased MR signal intensity was observed in the lymph nodes of two patients, which may represent inflammation or caseosis [15] . Osseous TB was not observed in any patient with either imaging modality. However, this is not surprising as participants were selected on the basis of having PTB. Bone involvement is rare in this condition. In addition, because of scanning time constraints, specific MRI of the spine, for example, was not performed.
Discussion
In general, this study has shown that PET/MR is qualitatively comparable to PET/CT, with all except four lesions observed on PET/CT also being visualized on PET/MR. The lesions that were not detected with PET/ MR had low SUVs as measured on PET/CT. In addition, these were small (< 1 cm along the longest axis) and may be at the limits of what is detectable with MRI. The location of the missed lesions in the middle and lower lobes suggests that respiratory motion may have played a role in the misdetection of these lesions. There were no patients in whom this would have meant a diagnosis of active TB being missed because there were 18 F-FDGavid lesions, indicative of PTB, visible on PET/MR, in all cases.
Measures of overall image quality and anatomical alignment were also similar between PET/MR and PET/CT. This is despite the additional challenges posed by the effects of respiratory motion and susceptibility artefacts in acquiring good-quality MRI of the lungs. In our protocol, we attempted to control for this by acquiring MR data using both breath-held (HASTE and VIBE) and navigated sequences (SPACE). Nevertheless, artefacts because of respiratory motion were present as some TB patients had difficulty complying with breath-holding instructions. Significantly lower SUVs were observed on PET/MR compared with PET/CT, both for SUV mean and for SUV max . Although we sought to mitigate the impact of changes in uptake over time, by varying the order of scans (half had PET/MR first and half had PET/CT first) and by minimizing the time between the two scans (maximum: 62 min), the time between injection and imaging was found to have a significant effect. This suggests that 18 F-FDG accumulation continues to change beyond 60 min in PTB lesions. Dual time-point imaging with 18 F-FDG PET/CT has previously shown a median increase of 13% in the SUV max of tuberculomas when comparing images at 60 and 120 min [16] Thus, although the time between 18 F-FDG dose and PET/MR was longer than with PET/CT, this time difference would likely explain only a small proportion of the observed difference in SUV between the two scanners and this is likely mainly because of attenuation correction errors caused by the linear attenuation coefficients assigned in the lung [17] .
In this study, most PTB lesions were identified by MRAC as either lung tissue or as a mixture of lung and soft tissue. When compared with the measured CT data, it is clear that application of these LACs will result in an underestimation of attenuation and will therefore result in an underestimation of the activity in the area of the lesion. Attenuation correction factors can be calculated from CT transmission data. It is not possible to directly measure radiodensity with MRI. Dixon-based MRAC is known to affect the quantitative accuracy of PET/MR data. The differences in SUVs between the two modalities observed in this study are larger than those observed when imaging other parts of the body [17, 18] . Mapping MRI intensities to appropriate attenuation coefficients has been shown to be problematic [19] . The current Dixon-based MRAC method assigns uniform attenuation coefficients in the lung.
The use of uniform coefficients results in both overestimation of regions that are closer to air and markedly underestimates the true attenuation coefficients of TB lesions. This effect is shown in Fig. 5 , where a large, cavitary lesion is clearly visible on the mu-map derived from CT, but is entirely absent from the MRAC-based mu-map. The lesion has been assigned a lung attenuation coefficient in the MR mu-map. The SUV max of the lesion was markedly lower with PET/MR compared with PET/CT. It is unclear how to accurately determine attenuation coefficients in, for example, areas of caseous necrosis commonly observed in TB. This study has shown that there is large variability in the density of PTB Bland-Altman plots of SUV max (a) and SUV mean (b). The dashed lines represent the mean SD 1.96. CT, computed tomography; SUV, standardized uptake value; SUV max , maximum standardized uptake value; SUV mean , mean standardized uptake value. The mean Hounsfield unit (HU) for each lesion measured on the PET/ computed tomography study, divided into groups on the basis of MR mu-map tissue classification. The lung tissue (LUNG), soft tissue (SOFT) and mixed (MIX) lesion groups are shown; no lesions were identified as fat.
lesions, further suggesting that a uniform attenuation coefficient is insufficient to accurately represent the types of lesions observed in TB.
Although this study has shown that overall the SUVs may be lower when imaging with PET/MR, this reduction would be consistent between longitudinal scans; thus, increases or decreases in SUV within a single patient can be used to monitor treatment response using PET/MR in research applications in PTB.
Conclusion
This study has shown that visual detection of PTB lesions is comparable between PET/MR and PET/CT. Although the values of SUV max and SUV mean are significantly lower with PET/MR, research applications measuring the response of lung lesions in response to therapy are unlikely to be affected by these differences in quantification. PET/MR offers the advantage of reduced radiation exposure to participants with an essentially curable disease.
